top of page

CRO and GCP Qualification Audits (ICH E6, 21 CFR 312, Phase 1/FIH)

CRO qualification is a GCP responsibility

Sponsors remain responsible for the conduct of their clinical trials, even when a contract research organization holds the day-to-day activity. Qualifying a CRO, a clinical laboratory, or a specialized trial vendor is not a paperwork exercise. It is a GCP audit of whether that partner can protect subjects, produce reliable data, and operate under the protocol, the quality system, and the applicable regulations.

​

GxP Auditing and Consulting Services provides CRO and GCP qualification audits led by Ramzi W. Kozal, CQA, an independent GxP lead auditor with nearly 30 years of experience, including IND-regulated early-phase clinical programs. The work is aligned to Good Clinical Practice, ICH E6, and 21 CFR Part 312, with particular attention to Phase 1 and first-in-human studies when that is the risk in front of you.

​

Ramzi has led 300+ GxP audits across the US and Europe, including Italy, and has hosted and defended 20+ FDA inspections with zero critical observations. CRO audits use the same disciplined approach: defined scope, evidence-based findings, and a report you can act on.

​

​

What ICH E6 and 21 CFR 312 require in practice

ICH E6 sets the GCP expectations that sponsors, investigators, and CROs are measured against, including quality management, investigator and vendor oversight, essential records, data integrity, and the handling of safety information. 21 CFR Part 312 is the U.S. investigational new drug framework. Together, they are why a sponsor cannot simply assume a well-known CRO is qualified for this protocol, this phase, and this product type.

​

A CRO qualification audit looks at the partner’s quality system and at the operational controls that will touch your study. That can include SOP coverage, training, vendor management, computerized systems, data handling, monitoring or oversight models, safety reporting, and how protocol deviations and CAPA are managed. For a study-specific audit, the sample also includes trial records and whether actual practice matches what the quality system claims.

​

The audit can be a pre-qualification assessment, a routine requalification, a study or investigator-site related GCP audit, or a for-cause review after a deviation, data issue, or inspection concern.

​

​

Phase 1 and first-in-human programs

Early-phase and first-in-human studies have a different risk profile than later clinical work. The subject population may be small, the product may be an advanced biologic, a radiopharmaceutical, or an IND-stage therapy, and the first evidence of safety and handling practice is being generated in real time. Oversight of the CRO, the clinical site, the pharmacy or radiopharmacy, and the laboratories has to be tight enough for that reality.

​

Ramzi’s background includes IND-regulated early-phase clinical programs and work in radiopharmaceuticals, cell and gene therapy, and mRNA and LNP platforms. That context is useful when a Phase 1 program depends on specialized manufacturing, qualified materials, or imaging and handling controls that a generalist clinical auditor may not see often.

​

​

How a GCP or CRO audit is conducted

The engagement starts by fixing the purpose: qualify this CRO, assess this study, review this vendor, or prepare for an inspection question about sponsor oversight. Document requests and interviews are then set against ICH E6 and 21 CFR 312, not against a generic quality checklist.

​

Remote audits are available worldwide, and on-site audits across the US and internationally. Remote work is often effective for quality-system and TMF or trial-master-file sampling when the CRO can provide controlled access. On-site work is more useful when facility, pharmacy, or clinical-site practice must be observed, or when interviews and record retrieval need to happen in the working environment.

​

You receive a written report with findings ranked by risk and a discussion of what should be corrected before the CRO is qualified or before the study proceeds without additional controls. Follow-up can include CAPA review or a narrower re-audit of closed issues.

​

​

Related clinical and vendor support

If the partner in question is a CMO or CDMO rather than a CRO, the vendor and CDMO qualification page is the right service. If the issue is electronic records, audit trails, or validation of clinical or quality systems, see the data integrity and CSV page. Inspection-readiness support, including mock FDA or EMA inspections, is available when a sponsor wants to test oversight before an authority asks the same questions.

​

To discuss a CRO qualification or GCP audit, contact GxP Auditing and Consulting Services, call (239) 207-8132, or review the pricing and packages page for current rates and add-on support.

Frequently Asked Questions

What regulations do your CRO audits follow?

CRO and GCP qualification audits are aligned to Good Clinical Practice, ICH E6, and 21 CFR Part 312. The exact emphasis depends on whether the work is a system qualification, a study audit, or a Phase 1 or first-in-human program.

 

Do you only audit large global CROs?

No. The audit is scoped to the partner you need to qualify, including specialty or early-phase vendors. The standard is whether that organization can meet GCP and 21 CFR 312 expectations for your study, not the size of the CRO.

​

Can you audit first-in-human or IND-stage programs?

Yes. The practice includes experience with IND-regulated early-phase clinical programs, which is often the point at which CRO, site, and product-handling controls need the closest review.

​

Is a GCP audit the same as a GMP vendor audit?

No. A GMP vendor or CDMO audit assesses manufacturing and quality-system compliance, often under 21 CFR 210/211 or 212. A CRO audit is a GCP assessment of trial conduct, data, and sponsor-vendor oversight. Many sponsors need both, but they are different scopes.

​

Can this work be done remotely?

Yes, when records and interviews can be provided in a controlled way. On-site audits are recommended when clinical-site, pharmacy, or facility practice is central to the risk.

bottom of page